Overview

Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma

Status:
Not yet recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of lenvatinib and pembrolizumab to treat metastatic uveal melanoma.
Phase:
Phase 2
Details
Lead Sponsor:
Providence Health & Services
Collaborators:
Eisai Inc.
Merck Sharp & Dohme Corp.
Treatments:
Lenvatinib
Pembrolizumab